Critical Comparison: UroGen Pharma (NASDAQ:URGN) vs. Shattuck Labs (NASDAQ:STTK)

UroGen Pharma (NASDAQ:URGNGet Rating) and Shattuck Labs (NASDAQ:STTKGet Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.


This table compares UroGen Pharma and Shattuck Labs’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
UroGen Pharma -209.30% -572.49% -78.96%
Shattuck Labs N/A -21.79% -19.17%

Analyst Ratings

This is a breakdown of recent ratings for UroGen Pharma and Shattuck Labs, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
UroGen Pharma 0 1 2 0 2.67
Shattuck Labs 0 0 3 0 3.00

UroGen Pharma currently has a consensus target price of $19.00, indicating a potential upside of 140.81%. Shattuck Labs has a consensus target price of $24.00, indicating a potential upside of 501.50%. Given Shattuck Labs’ stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than UroGen Pharma.

Insider and Institutional Ownership

62.2% of Shattuck Labs shares are held by institutional investors. 12.8% of UroGen Pharma shares are held by insiders. Comparatively, 18.7% of Shattuck Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares UroGen Pharma and Shattuck Labs’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
UroGen Pharma $48.04 million 3.43 -$110.82 million ($5.04) -1.57
Shattuck Labs $30.02 million 5.63 -$44.97 million ($1.37) -2.91

Shattuck Labs has lower revenue, but higher earnings than UroGen Pharma. Shattuck Labs is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

UroGen Pharma has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500.


Shattuck Labs beats UroGen Pharma on 12 of the 14 factors compared between the two stocks.

About UroGen Pharma (Get Rating)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

About Shattuck Labs (Get Rating)

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with's FREE daily email newsletter.